Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha‐2b in metastatic melanoma (phase II DeCOG trial)
暂无分享,去创建一个
Axel Hauschild | Michael Weichenthal | Claus Garbe | Selma Ugurel | M. Weichenthal | A. Hauschild | S. Ugurel | F. Egberts | K. Kilian | C. Garbe | R. Gutzmer | A. Degen | U. Trefzer | Ralf Gutzmer | Uwe Trefzer | Friederike Egberts | Annette Degen | Katharina Kilian | Lìdia Marilia Poppe | L. M. Poppe | Katharina Kilian
[1] W. Rathmell,et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Caraglia,et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. , 2010, The oncologist.
[3] A. Hauschild,et al. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low‐dose interferon alpha , 2007, International journal of cancer.
[4] A. Hauschild,et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2008, The Lancet.
[5] E. Jonasch,et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. , 2009, Clinical genitourinary cancer.
[6] J. Kirkwood,et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon , 2006, Seminars in Immunopathology.
[7] S. Aamdal,et al. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. , 2009, Journal of the National Cancer Institute.
[8] A. Hauschild,et al. Does Basal Cell Carcinoma Belong to the Spectrum of Sorafenib-Induced Epithelial Skin Cancers? , 2010, Dermatology.
[9] C. Robert,et al. RAF inhibition and induction of cutaneous squamous cell carcinoma , 2011, Current opinion in oncology.
[10] M. Weichenthal,et al. Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] D. Schadendorf,et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. , 2012, European journal of cancer.
[12] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[13] C. Robert,et al. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. , 2009, Journal of the American Academy of Dermatology.
[14] A. Udvardi,et al. Perforating folliculitis, angioedema, hand‐foot syndrome – multiple cutaneous side effects in a patient treated with sorafenib , 2009, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[15] Dirk Strumberg,et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] C. Robert,et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. , 2008, Archives of dermatology.
[17] D. Schadendorf,et al. Side effects of systemic oncological therapies in dermatology , 2012, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[18] H. Kong,et al. Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy , 2009, Clinical Cancer Research.
[19] C. Tangen,et al. Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] L. Heinzerling,et al. Sarcoidosis Induced by Interferon-α in Melanoma Patients: Incidence, Clinical Manifestations, and Management Strategies , 2010, Journal of immunotherapy.
[21] J. Guilhou,et al. A Prospective Study of Cutaneous Adverse Events Induced by Low-Dose Alpha-Interferon Treatment for Malignant Melanoma , 2004, Dermatology.
[22] D. Strumberg,et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome? , 2006, European journal of cancer.
[23] D. West,et al. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib , 2008, Supportive Care in Cancer.
[24] J. Soria,et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Valérie Joncas,et al. A distinct cutaneous reaction to sorafenib and a multikinase inhibitor , 2008, International journal of dermatology.
[26] M. Alter,et al. The hand‐foot‐syndrome associated with medical tumor therapy – classification and management , 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[27] R. Perez-soler,et al. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] W. Sterry,et al. [Cutaneous side effects of clinically relevant cytokine therapies]. , 2003, Deutsche medizinische Wochenschrift.